



State of Utah

SPENCER J. COX
Governor

DEIDRE M. HENDERSON
Lieutenant Governor

Insurance Department

JONATHAN T. PIKE
Insurance Commissioner

2025 Utah Pharmacy Premium Impact Report

The *2025 Pharmacy Premium Impact Report* was published by the Utah Insurance Department on November 17, 2025. For questions, please contact the Health & Life Division at (801) 957-9280 or healthresearch@utah.gov.

Background

Utah Code § 31A-48-103(2) requires health insurers to submit pharmacy drug information to the Utah Insurance Department (Department) on or before August 1st each year. The Department must publish this information on its website by December 1st each year. The Department must also ensure that the identity of the health insurers is protected.

A health insurer shall report to the Department, in aggregate, the following information for health benefit plans offered by the insurer:

- 1) For the 25 drugs for which spending by the health insurer was the greatest, after adjusting for rebates: the name of the drug, the dosage form of the drug, and the strength of the drug.
- 2) The percentage increase over the previous year in net spending for all drugs, after adjusting for rebates.
- 3) The percentage of the increase in premiums over the previous year attributable to all drugs and specialty drugs.

Data was collected from health insurers issuing comprehensive health insurance health benefit plans in Utah during 2024. These companies represent nearly 99 percent of the comprehensive health insurance market and provide coverage for an estimated 24.2 percent of Utah residents. These companies only represent fully insured comprehensive health benefit plans. The data does not include any information from employer sponsored health benefit plans or government sponsored health benefit plans. Utah health insurers not actively issuing comprehensive health insurance health benefit plans were excluded.

The data was aggregated to produce market level estimates of the Top 25 drugs with the largest spending by health insurers, after adjusting for rebates, in the comprehensive health insurance market. Premium impact was measured by estimating the percentage of comprehensive health insurance premiums attributable to pharmacy drug costs for the Top 25 drugs, generic drugs, brand name drugs, specialty drugs, and all drugs.

Generic drugs. A generic drug, as classified by the United States Food and Drug Administration (FDA), is therapeutically equivalent to a brand name drug in dosage, safety, strength, how it is taken, quality, performance, and intended use. A generic drug is not under patent protection and may be produced by more than one pharmacy drug manufacturer.

Brand name drugs. A brand name drug, as classified by the United States Food and Drug Administration (FDA), is a drug marketed under a proprietary, trademark-protected name. The drug has patent protection and is usually produced by only one pharmacy drug manufacturer until the patent protection has expired.

Specialty drugs. A generic or brand name drug classified as a specialty drug on the health insurer's drug formulary list are prescription drug products that require special handling, has high costs, or are only available through specialty pharmacies.

Total (All drugs). Total (all drugs) includes all generic, brand name, and specialty drugs as reported by the health insurer.

Top 25 drugs. The Top 25 drugs described in this report are a subset of all drugs and may include generic, brand name, or specialty drugs. Each health insurer was asked to report the Top 25 drugs with the largest insurer spending, after adjusting for rebates, by the National Drug Code (NDC). This information was combined to generate the Top 25 drugs with the largest insurer spending for the comprehensive health insurance market.

Cost Per Member Per Month (PMPM). Pharmacy drug spending was measured by cost (PMPM). Cost PMPM is the total pharmacy drug spending by the health insurer, after adjusting for rebates, divided by cumulative member months. A member month is the total number of members covered by the health insurer's health benefit plan for a single month. Cumulative member months is the sum total of member months for the calendar year. This method standardizes pharmacy drug costs per member per month for a health insurer.

Premium. Premium income was measured using the same method as cost PMPM. The total direct earned premium reported by the health insurer was divided by the total cumulative member months. Direct earned premium is the premium income received by the health insurer from all sources (after risk adjustment) that was allocated to the health insurer's loss experience, expenses, and profit during the year.

Executive Summary

- The total spending for the Top 25 drugs accounted for 31.7 percent of total drug spending for all drugs in 2024.
- The total spending for the Top 25 drugs accounted for 7.2 percent of premiums in 2024.
- The Top 5 drugs with the highest insurer spending in Utah were Stelara, Trikafta, Skyrizi, Humira, and Rinvoq.
- Spending for all drugs decreased by 6.8 percent between 2023 and 2024 due to decreases in generic and specialty drugs.
- The percentage of premium attributable to all drugs was 23.8 percent, a decrease of 3.1 percent between 2023 and 2024.

Top 25 Drugs in the Comprehensive Health Insurance Market

Table 1 shows the Top 25 drugs with the largest health insurer spending in the comprehensive health insurance market in Utah. Drugs were ranked by the total dollar amount of drug spending by health insurers for the market as a whole. Table 1 lists these drugs by their proprietary name and includes the 11-digit NDC for the dosage, as well as the package form of the drug. The non-proprietary name of the drug and its manufacturer are provided in Table 2 (see Table 2).

The Top 25 drugs accounted for 31.7 percent of total drug spending across all types of drugs and were attributable to 7.2 percent of comprehensive health insurance premiums. The top 5 drugs that accounted for the largest percentage of comprehensive health insurance premiums were Stelara, Trikafta, Skyrizi Humira, and Rinvoq. These five drugs accounted for 41.3 percent of the drug spending for the Top 25 drugs and made up 3.0 percent of comprehensive health insurance premiums. In most cases, the Top 25 drugs were classified as specialty drugs. However, seven drugs were classified as brand name drugs by at least one health insurer, denoted by the “B” in Table 1. None of the Top 25 drugs were generic drugs.

Table 1. 2024 Top 25 Drugs in the Comprehensive Health Insurance Market by Health Insurer Pharmacy Drug Spending

Rank	Proprietary name	Drug type	11-digit NDC(s)	Dosage Form	Strength	Cost PMPM	Percent of Premium
1	STELARA	S	57894006002	Injection	45 mg/0.5 mL	\$3.32	0.74%
		S	57894006003		45 mg/0.5 mL		
		S	57894006103		90 mg/mL		
2	TRIKAFTA ^a	S	51167010602	Tablet	50 mg, 25 mg, 37.5 mg; 75 mg	\$3.18	0.71%
		S	51167033101		100 mg, 50 mg, 75 mg; 150 mg		
3	SKYRIZI	S	00074105001	Injection	150 mg/mL	\$2.66	0.59%
		S	00074107001		360 mg/2.4 mL		
		S	00074210001		150 mg/mL		
4	HUMIRA	S	00074012402	Injection	80 mg/0.8 mL	\$2.19	0.49%
		S	00074012403		80 mg/0.8 mL		
		S	00074024302		40 mg/0.4 mL		
		S	00074055402		40 mg/0.4 mL		
		S	00074433902		40 mg/0.8 mL		
5	RINVOQ	S	00074230630	Tablet	15 mg	\$2.10	0.47%
		S	00074231030		30 mg		
6	COSENTYX	S	00078063941	Injection	150 mg/mL	\$1.98	0.44%
		S	00078107068		300 mg/2 mL		
7	KEYTRUDA	S	00006302601	Injection	100 mg/4 mL	\$1.80	0.40%
		S	00006302602		100 mg/4 mL		
		S	00006302604		100 mg/4 mL		
8	BIKTARVY ^b	S	61958250101	Tablet	50 mg/200 mg/25 mg	\$1.64	0.36%
9	TYSABRI	S	64406000801	Injection	300 mg/15 mL	\$1.54	0.34%
10	OCREVUS	S	50242015001	Injection	300 mg/10 mL	\$1.52	0.34%
11	ENTYVIO	S	64764030020	Injection	300 mg	\$1.44	0.32%
12	FARXIGA	B	00310621030	Tablet	10 mg	\$1.25	0.28%
13	ENBREL	S	58406003204	Injection	50 mg/mL	\$0.97	0.22%
			58406001004		25 mg/0.5 mL		
14	ELIQUIS	B	00003089421	Tablet	5 mg	\$0.89	0.20%

15	AMJEVITA	S	72511040002	Injection	40 mg/0.8 mL	\$0.78	0.17%
16	DUPIXENT	S	00024591401	Injection	300 mg/2 mL	\$0.77	0.17%
		S	00024591502		300 mg/2 mL		
17	XOLAIR	S	50242021501	Injection	150 mg/mL	\$0.76	0.17%
18	JARDIANCE	B	00597015230	Tablet	10 mg	\$0.65	0.15%
		B	00597015330		25 mg		
19	MOUNJARO	B	00002145780	Injection	15 mg/0.5 mL	\$0.58	0.13%
		B	00002146080		12.5 mg/0.5 mL		
		B	00002147180		10 mg/0.5 mL		
		B	00002148480		7.5 mg/0.5 mL		
		B	00002149580		5 mg/0.5 mL		
B	00002150680	2.5 mg/0.5 mL					
20	SPRAVATO	S	50458002803	Spray	84 mg	\$0.56	0.12%
21	NURTEC	B	72618300002	Tablet	75 mg	\$0.53	0.12%
		B	00002143480		1.5 mg/0.5 mL		
22	TRULICITY	B	00002223680	Injection	3 mg/0.5 mL	\$0.45	0.10%
		B	00002318280		4.5 mg/0.5 mL		
23	BRIUMVI	S	73150015006	Injection	150 mg/6 mL	\$0.43	0.09%
24	HEMLIBRA	S	50242092101	Injection	60 mg/0.4 mL	\$0.36	0.08%
		S	50242092201		105 mg/0.7 mL		
25	OZEMPIC	B	00169413013	Injection	4 mg/3 mL	\$0.27	0.06%
		B	00169418113		2 mg/3 mL		
		B	00169477212		8 mg/3 mL		

Source: Utah Insurance Department

Note: B = Brand name, G = Generic, S = Specialty. Estimates may not add up exactly due to rounding. All data is current as of Dec. 31, 2024.

^a Trikafta: 4-wallets (each containing 14 tablets of elexacaftor, tezacaftor, and ivacaftor and 7 tablets of ivacaftor)

^b Biktarvy: contains bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate

Table 2. 2024 Top 25 Drugs in the Comprehensive Health Insurance Market by Drug Manufacturer

Rank	Proprietary Name	Nonproprietary name	Labeler Code	Company Name
1	STELARA	ustekinumab	57894	Janssen Biotech, Inc.
2	TRIKAFTA	elexacaftor, tezacaftor, and ivacaftor	51167	Vertex Pharmaceuticals Incorporated
3	SKYRIZI	risankizumab-rzaa	00074	AbbVie Inc.
4	HUMIRA	adalimumab	00074	AbbVie Inc.
5	RINVOQ	upadacitinib	00074	AbbVie Inc.
6	COSENTYX	secukinumab	00078	Novartis Pharmaceuticals Corporation
7	KEYTRUDA	pembrolizumab	00006	Merck Sharp & Dohme LLC
8	BIKTARVY	bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate	61958	Gilead Sciences, Inc.
9	TYSABRI	natalizumab	64406	Biogen Inc.
10	OCREVUS	ocrelizumab	50242	Genentech, Inc.
11	ENTYVIO	vedolizumab	64764	Takeda Pharmaceuticals America, Inc.
12	FARXIGA	dapagliflozin	00310	AstraZeneca Pharmaceuticals LP
13	ENBREL	etanercept	58406	Immunex Corporation
14	ELIQUIS	apixaban	00003	E.R. Squibb & Sons, L.L.C.
15	AMJEVITA	adalimumab-atto	55513	Amgen Inc
16	DUPIXENT	dupilumab	00024	Sanofi-Aventis U.S. LLC
17	XOLAIR	omalizumab	50242	Genentech, Inc.
18	JARDIANCE	empagliflozin	00597	Boehringer Ingelheim Pharmaceuticals, Inc.
19	MOUNJARO	tirzepatide	00002	Eli Lilly and Company
20	SPRAVATO	esketamine hydrochloride	50458	Janssen Pharmaceuticals Inc.
21	NURTEC	rimegepant sulfate	72618	Pfizer Laboratories Div Pfizer Inc
22	TRULICITY	dulaglutide	00002	Eli Lilly and Company
23	BRIUMVI	ublituximab	73150	TG Therapeutics, Inc.
24	HEMLIBRA	emicizumab	50242	Genentech, Inc.
25	OZEMPIC	semaglutide	00169	Novo Nordisk

Source: Utah Insurance Department

Pharmacy Drug Spending

In addition to reporting the Top 25 drugs by total drug spending, health insurers also reported the total drug spending for generic, brand, specialty, and all drugs. Drug spending was measured by the amount paid by the health insurer for each drug type category.

Generic drugs accounted for 9.7 percent of spending across all drugs. Brand name drugs accounted for 27.9 percent, and specialty drugs accounted for 62.4 percent of total drug spending for all drugs. Total drug spending for all drugs decreased by 6.8 percent from 2023 to 2024. Over that same period, generic drug spending decreased by 8.1 percent, brand name drug spending increased by 9.1 percent, and specialty drug spending decreased by 12.3 percent (see Table 3).

Drug spending increased only for brand name drugs from 2023 to 2024, and decreased for generic and specialty drugs. During this same period, comprehensive health insurance premiums PMPM increased 6.4 percent.

Table 3. Health Insurer Pharmacy Drug Spending as a Percent of Pharmacy Drug Costs

Drug Type	Cost PMPM	Percent of Drug Spending	Percent Change in Cost PMPM
Generic	10.42	9.7%	-8.1%
Brand	29.84	27.9%	9.1%
Specialty	66.80	62.4%	-12.3%
All Drugs	107.06	100.0%	-6.8%

Source: Utah Insurance Department

Note: Percent change is the annual percent change from the previous year. Estimates may not add up exactly due to rounding. All data is current as of Dec. 31, 2024.

Premium Attributable to Pharmacy Drug Spending

In 2024, the percentage of comprehensive health insurance premiums attributable to total drug spending was 23.8 percent for all drugs and 14.8 percent for specialty drugs (see Table 4). Brand name drugs accounted for 6.6% of premiums, and generic drugs made up 2.3% in 2024.

Based on the available data, the Department estimates that the percentage of comprehensive health insurance premiums attributable to total drug spending for all drugs decreased 3 percent from 2023 to 2024. The decrease in total drug spending appears to be due to a decrease in spending for generic and specialty drugs (see Table 4).

Table 4. Percent of Premium Attributable to Health Insurer Pharmacy Drug Spending

Drug Type	Cost PMPM	Percent of Premium	Net Change in Percent of Premium^A
Generic	10.42	2.3%	-0.3%
Brand	29.84	6.6%	0.3%
Specialty	66.80	14.8%	-2.9%
All Drugs	107.06	23.8%	-3.1%
Premium	449.90	100.0%	

Source: Utah Insurance Department

Note: Percent change is the annual percent change from the previous year. Net change is the difference in the percent of premium from the previous year. Estimates may not add up exactly due to rounding. All data is current as of Dec. 31, 2024.

A: Change is calculated between 2023 and 2024 premiums PMPM